Piotr Wysocki: Pembrolizumab prevents recurrence in BCG-resistant bladder cancer
Piotr Wysocki recently posted on LinkedIn:
“Necchi A et al. published a phase II single-arm study results in Lancet Oncology. The study enrolled 132 patients with BCG-refractory (median 10 previous BCG instillations) non-muscle invasive bladder cancer (excluding carcinoma in situ).
Within 12 weeks of transurethral resection of the bladder tumor, patients received the first dose of pembrolizumab (administered intravenously every 3 weeks for up to 35 cycles).
The primary endpoint was 12-month disease-free survival (DFS). After a median follow-up of 45.4 months:
- The 12-months DFS was 43.5% (95%CI 34.9–51.9)
- The median DFS was 7.7 months (95%CI 5.5–13.6)
- Long-term DFS (>48 months) was observed in approx 30-35% of patients
Treatment-related adverse events occurred in 73% of patients with G3-G4 AEs observed in 14% of patients.
The study demonstrates that pembrolizumab protects patients from recurrence of superficial (Ta or T1), BCG-resistant bladder cancer and, taking into account its systemic mechanism of action, may thus lower the risk of development of muscle-invasive urothelial cancer.”
Authors: Andrea Necchi, Mathieu Roumiguié, Ashish Kamat, Neal Shore, Joost Boormans, Ahmet Adil Esen, Thierry Lebret, Shuya Kandori, Dean F Bajorin, Laurence Krieger, Scot Niglio, Edward Uchio, Ho Kyung Seo, Ronald de Wit, Eric Singer, Petros Grivas, Hiroyuki Nishiyama, Haojie Li, Pranshu Baranwal, Margot Van den Sigtenhorst-Fijlstra, Ekta Kapadia, Girish Kulkarni
Source: Piotr Wysocki/LinkedIn
Piotr Wysocki leads the Clinical Oncology Department at University Hospital and the Faculty of Oncology at Jagiellonian University-Medical College in Krakow, Poland. As an advisor to the Polish Ministry of Health, he shapes the national cancer strategy.
His clinical expertise spans the systemic treatment of breast, gynecologic, and genitourinary cancers, with a focus on developing innovative metronomic chemotherapy-based therapies for advanced cancer patients who have undergone prior treatment.
Read other posts by Piotr Wysocki published on OncoDaily.